New Patient Forms
Pay My Bill
Some Medical News, and Analysis
The following is meant only as thoughts and news, not medical advice.
Some News and Analysis
11/30/2018- More Combo medication Recalls:
Teva Pharmaceuticals has launched a voluntary recall into two drugs
used to treat high blood pressure as yet more medications face concerns over a possible cancer risk.
In a statement from Teva posted by the Food and Drug Administration,
the recall affects all lots of combination tablets featuring the drugs amlodipine and valsartan
and another combo drug featuring amlodipine, valsartan, and hydrochlorothiazide.
11/29/2018 - The opiod crisis, which is a young man suicide issue, is a North East USA problem, not Nebraska
Place also mattered when it came to drug overdose deaths, with some states registering higher numbers than others,
the report shows. The 2017 rate in West Virginia was nearly 58 overdose deaths per 100,000 people,
in Ohio about 46 per 100,000, in Pennsylvania about 44 per 100,000, and in the District of Columbia, 44 per 100,000.
Meanwhile, Texas (about 10 drug overdose deaths per 100,000), North Dakota (about 9 per 100,000),
South Dakota and Nebraska (both about 8 per 100,000) had the lowest rates in 2017.
11/2/2018 - Heart Drug Recall
The Food and Drug Administration is recalling the blood pressure drug irbesartan for a potential cancer risk due to contamination.
The maker of irbesartan, SciGen, is also recalling certain lots of the drug.
The FDA recalled valsartan in July - another drug used to treat high blood pressure and heart failure - because of contamination.
Drugs containing valsartan were also recalled last month.
11/2/2018 - In the midst of an opiod crisis, a new opiod is approved:
The Food and Drug Administration (FDA) on Friday approved a powerful new opioid drug despite concerns from advocates that it could be abused.
The drug, called Dsuvia, is 10 times more powerful than fentanyl and 1,000 times more powerful than morphine, according to Public Citizen,
an advocacy group that objected to the approval.